AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 50 percent decrease over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $4.050 million which missed the analyst consensus estimate of $7.784 million by 47.97 percent. This is a 76.29 percent decrease over sales of $17.084 million the same period last year.